Literature DB >> 22153828

Diagnosis and treatment status of migraine: a clinic-based study in China.

Xuelian Li1, Jiying Zhou, Ge Tan, Yunfeng Wang, Li Ran, Lixue Chen.   

Abstract

OBJECTIVES: To investigate the prevalence and clinical characteristics of migraine, and to evaluate the current status of migraine diagnosis and treatment in neurological outpatients.
METHODS: A face-to-face interview survey was conducted in the neurological clinic of a tertiary care hospital during a period of three months. A headache questionnaire for patients who consulted doctors with a chief complaint of headache was completed by a qualified and experienced physician in headache studies during the interview. Migraine diagnosis was made by physicians based on the criteria of the second edition of the International Classification of Headache Disorders.
RESULTS: Of 9282 patients assessed, 19.5% (1806) complained of headache. The prevalence of migraine was 23.8%(401/1683)among headache patients. The average age of migraineurs was 42.2±13.1 years and 80.5% were female. Of all migraineurs, 68.6% had consulted a physician for headache in the previous one year, and only 13.5% had received a physician diagnosis of migraine. A total of 173 migraine patients (43.1%) had not taken any analgesic for acute treatment in the previous three months and only 11 migraineurs (2.7%) had used preventative medications. Medication overuse was significantly more common in male than in female patients with migraine (P<0.01).
CONCLUSIONS: Migraine is the most common headache disorder in the neurological clinic and it remains underrecognized and undertreated in China. Public health initiatives to improve diagnosis and treatment of migraine are needed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22153828     DOI: 10.1016/j.jns.2011.11.021

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Awareness of Migraine Among Primary Care Physicians in Turkey: A Regional Study.

Authors:  Murat Gültekin; Elçin Balci; Sevda İsmaİLOĞULLARI; Fatih Yetkin; Recep Baydemir; Füsun Erdoğan; Meral Mİrza; Aynur Özge
Journal:  Noro Psikiyatr Ars       Date:  2018-07-06       Impact factor: 1.339

2.  Lifting the burden of headache in China: managing migraine in a SMART way.

Authors:  Shengyuan Yu; Timothy J Steiner
Journal:  J Headache Pain       Date:  2017-08-08       Impact factor: 7.277

3.  Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database.

Authors:  Shengyuan Yu; Yanlei Zhang; Yuan Yao; Haijun Cao
Journal:  J Headache Pain       Date:  2020-05-13       Impact factor: 7.277

Review 4.  Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature.

Authors:  Takao Takeshima; Qi Wan; Yanlei Zhang; Mika Komori; Serina Stretton; Narayan Rajan; Tamas Treuer; Kaname Ueda
Journal:  J Headache Pain       Date:  2019-12-05       Impact factor: 7.277

5.  Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.

Authors:  Bo Hu; Gang Li; Xiaohong Li; Shan Wu; Tingmin Yu; Xiang Li; Hongru Zhao; Zhihua Jia; Junpeng Zhuang; Shengyuan Yu
Journal:  J Headache Pain       Date:  2022-07-28       Impact factor: 8.588

6.  Children with cyclic vomiting syndrome: phenotypes, disease burden and mitochondrial DNA analysis.

Authors:  Ziqing Ye; Aijuan Xue; Ying Huang; Qiye Wu
Journal:  BMC Gastroenterol       Date:  2018-07-03       Impact factor: 3.067

7.  Prevalence of migraine in Han Chinese of Fujian province: An epidemiological study.

Authors:  Qi-Fang Lin; Qiao-Qing Xia; Yu-Li Zeng; Xiao-Yang Wu; Lin-Feng Ye; Long-Teng Yao; Yong-Tong Xin; Gen-Bin Huang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 8.  Advances in topiramate as prophylactic treatment for migraine.

Authors:  Chuan Hu; Yixin Zhang; Ge Tan
Journal:  Brain Behav       Date:  2021-09-02       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.